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Meropenem is a clinically important antibacterial reserved for treatment of 27 
multi-resistant infections. In meropenem-resistant bacteria of the family 28 
Enterobacterales, NDM-1 is considerably more common than IMP-1, despite 29 
both metallo-β-lactamases (MBLs) hydrolysing meropenem with almost 30 
identical kinetics. We show that blaNDM-1 consistently confers meropenem 31 
resistance in wild-type Enterobacterales, but blaIMP-1 does not. The reason is 32 
higher blaNDM-1 expression because of its stronger promoter. However, the cost 33 
of meropenem resistance is reduced fitness of blaNDM-1 positive 34 
Enterobacterales. In parallel, from a clinical case, we identified multiple 35 
Enterobacter spp. isolates carrying a plasmid-encoded blaNDM-1 having a 36 
modified promoter region. This modification lowered MBL production to a level 37 
associated with zero fitness cost but, consequently, the isolates were not 38 
meropenem resistant. However, we identified a Klebsiella pneumoniae isolate 39 
from this same clinical case carrying the same blaNDM-1 plasmid. This isolate 40 
was meropenem resistant despite low-level NDM-1 production because of a 41 
ramR mutation, reducing envelope permeability. Overall, therefore, we show 42 
how the resistance/fitness trade-off for MBL carriage can be resolved. The 43 





β-Lactamases are the most frequent cause of β-lactam resistance among Gram-46 
negative bacteria. In β-lactamases of molecular classes A, C and D, an active site 47 
serine catalyses hydrolysis of the β-lactam ring. Members of class B utilize zinc ions 48 
in catalysis and are known as metallo-β-lactamases (MBLs). Based on their 49 
sequence homology, MBLs are classified into three subclasses: B1, B2 and B3 (1). 50 
Chromosomally encoded MBLs belonging to subclasses B2 and B3 have been 51 
isolated from environmental and opportunistic pathogenic bacteria such CphA 52 
(Aeromonas hydrophila) (2), L1 (Stenotrophomonas maltophilia) (3), IND 53 
(Chryseobacterium indologenes) (4), and Sfh-1 (Serratia fonticola) (5). However, the 54 
most common MBLs in human pathogens are from subclass B1 and are encoded on 55 
mobile genetic elements, particularly VIM (6), IMP (7), and NDM (8). These enzymes 56 
can efficiently catalyse the hydrolysis of all clinically relevant β-lactams except the 57 
monobactams (1). 58 
The genes encoding VIM-1 and IMP-1 are held within class 1 integrons as gene 59 
cassettes (6,7). Integrons are gene capture systems consisting of a 5’ conserved 60 
sequence including intI, encoding an integrase enzyme, an array of gene cassettes, 61 
and a 3’ conserved sequence. Gene cassettes are promoter-less and consist of an 62 
open reading frame and an adjacent recombination site, attC, specifically recognized 63 
by the integrase enzyme. A common promoter (Pc) located within the intI sequence 64 
directs expression of all gene cassettes in an integron (9). There are essentially 65 
three strengths of Pc: PcS – strong, PcW – weak, and PcH – intermediate (10).  66 
The blaNDM-1 gene is not a gene cassette but has been mobilised by an insertion 67 
sequence (IS) element, ISAba125 (11). This mobilisation also drives expression of 68 




In a recent UK study, NDM-1 was found to be the dominant MBL in carbapenem 70 
resistant Enterobacterales clinical isolates, with IMP-1 not being found at all (13). 71 
One possible explanation is that NDM-1 is a lipoprotein and has evolved to perform 72 
well in the sort of low zinc environment often seen at sites of infection (14), 73 
something which is enhanced in various NDM variants, particularly NDM-4 (15). 74 
However, it is possible that positive selection for NDM-1 production is driven by 75 
something more fundamental. There is some evidence that IMP-1-encoding 76 
plasmids only confer borderline resistance to carbapenems in E. coli even when zinc 77 
concentration are high (e.g. as seen in Ref 16), whereas minimum inhibitory 78 
concentrations (MICs) of carbapenems against E. coli transconjugants carrying 79 
NDM-1 plasmids are much higher (e.g. as seen in Ref 8). We hypothesise that a 80 
more consistent ability to confer carbapenem resistance is part of the reason why 81 
NDM-1 is dominant over IMP-1 among carbapenem resistant isolates. If correct, this 82 
would imply that the levels of active enzyme produced are frequently greater for 83 
NDM-1- than for IMP-1-positive Enterobacterales because, catalytically, the 84 
enzymes are very similar (8).  85 
The aims of the work presented here was to test the hypothesis that NDM-1 and 86 
IMP-1 confer different carbapenem MICs, because they are produced at different 87 
levels from their native expression environments, and that NDM-1 more commonly 88 
confers carbapenem resistance than IMP-1. Furthermore, we have investigated the 89 
fitness trade-offs that come in to play when higher level MBL production is necessary 90 
to confer resistance. Finally, we report a clinical case demonstrating how these 91 
fitness trade-offs manifest in the real world. 92 




Results and Discussion 94 
blaNDM-1 is expressed at higher levels than blaIMP-1 and confers meropenem 95 
resistance in Enterobacterales clinical isolates. 96 
A blastn search of GenBank using the nucleotide sequences of blaIMP-1 and blaNDM-1 97 
revealed that, of entries that matched with 100% coverage and identity, E. coli 98 
(2=9.82, p<0.005) and Klebsiella spp. (2=12.72, p<0.0005) are more likely to carry 99 
blaNDM-1 than blaIMP-1. This analysis is supported by global surveillance data from 100 
clinical isolates. For example, from a recent SENTRY study where, of 1298 101 
carbapenem resistant Enterobacterales analysed in 2014-16, blaNDM positivity was 102 
12.7% whilst blaIMP positivity was 0.4% (17). In contrast, the non-Enterobacterales 103 
Pseudomonas spp. is more likely to carry blaIMP-1 than blaNDM-1 (2=30.18, 104 
p<0.00001).  105 
There may be many reasons why one gene conferring resistance to an antibacterial 106 
drug disseminates more widely than another, but we sought to test the hypothesis 107 
that blaNDM-1 is dominant over blaIMP-1 in carbapenem resistant Enterobacterales 108 
because only blaNDM-1 reliably confers carbapenem resistance. The blaNDM-1 gene is 109 
almost exclusively found downstream of an ISAba125 sequence, which provides an 110 
outward facing promoter, Pout, which drives blaNDM-1 expression (11). In contrast, 111 
blaIMP-1 is encoded as an integron gene cassette (7), and so can be present 112 
downstream of several different promoter (Pc) sequences (10). Of the 26 blaIMP-1 113 
GenBank entries involving E. coli, Klebsiella spp. and Enterobacter spp. where 114 
sufficient sequence was present to identify the Pc promoter variant, 24/26 were 115 
intermediate strength as previously defined (10) and of these, ten were PcH1 116 




located downstream of the PcH1 promoter with blaNDM-1 located downstream of Pout 118 
from ISAba125 on susceptibility to the carbapenem meropenem. 119 
Thirteen out of thirteen blaNDM-1 Enterobacterales clinical isolate transformants tested 120 
were meropenem resistant, defined using clinical breakpoints, but only 1/13 blaIMP-1 121 
transformants (Table S2). These data support our primary hypothesis, that NDM-1 122 
more readily confers meropenem resistance than IMP-1 in the Enterobacterales. 123 
IMP-1 and NDM-1 are, in terms of meropenem catalytic efficiency, very similar 124 
enzymes (8), so our next hypothesis was that more NDM-1 is produced than IMP-1 125 
in cells, explaining the difference in meropenem MIC. This hypothesis was also 126 
supported by experiment; the amount of meropenem hydrolysing activity in cell 127 
extracts of representative blaNDM-1 transformants of E. coli, K. pneumoniae and 128 
Enterobacter (Klebsiella) aerogenes was 3 to 6-fold higher than in blaIMP-1 129 
transformants (p<0.002 for each). As expected, elevated meropenem hydrolysing 130 
activity was due to greater production of NDM-1 than IMP-1 protein as measured 131 
using LC-MS/MS proteomics (Fig. 1).  132 
Changing the ribosome binding sequence upstream of blaNDM-1 to be identical to that 133 
found upstream of blaIMP-1 did not significantly reduce NDM-1 production or 134 
meropenem hydrolysing activity. However, generating the N* variant, by replacing 135 
the entire blaNDM-1 upstream sequence with that upstream of blaIMP-1, reduced NDM-1 136 
production to be very similar to that of IMP-1 in all three species (Fig. 1). 137 
 138 
The correlation between high gene expression and fitness cost when carrying blaNDM-139 




We next investigated whether the greater production of NDM-1 relative to IMP-1 141 
imposes a fitness cost. Using pairwise competition experiments, where 142 
transformants were directly competed over 4 days in the absence of β-lactams, we 143 
showed that there is no cost of carrying blaIMP-1 in E. coli and K. pneumoniae, but 144 
there was a significant cost of carrying blaNDM-1 in both species (Table 1).  145 
Higher production of NDM-1 versus IMP-1 could impose a fitness cost because of 146 
depletion of resources required to make the additional MBL (e.g. amino acids, 147 
energy and zinc), or it could be due to some toxicity that the MBL imposes, as has 148 
been seen in some cases, e.g. SPM and VIM, previously (18). To differentiate 149 
between these possibilities, we investigated the physiological impact of carrying 150 
blaIMP-1 or blaNDM-1 in E. coli. To do this, we used LC-MS/MS proteomics to quantify 151 
steady state protein abundance differences in transformants. 152 
Of 1390 proteins identified and quantified in the blaIMP-1 vs plasmid only control 153 
comparison, 66 were significantly up or down regulated (Table S3) but Chi squared 154 
analysis did not reveal clustering of these proteins into any KEGG functional group, 155 
suggesting that there is little concerted physiological response to carrying blaIMP-1 156 
(Table S4). The blaNDM-1 versus control comparison identified and quantified 1670 157 
proteins, of which 88 were differentially regulated (Table S5). In this case Chi 158 
squared analysis did identify clustering (Table S6) of these regulated proteins into a 159 
specific KEGG pathway: eco00260, glycine, serine, and threonine metabolism. 160 
Upregulated proteins include the committed enzymes GlyA (19), SerA (20), ThrC 161 
(21), and IlvA, which directs these amino acids into other amino acid biosynthetic 162 
pathways (22). Therefore, production of NDM-1, which is approximately 6-fold more 163 




(Table 1), which is associated with regulatory signals of amino acid starvation 165 
(Tables S3-S6). 166 
 167 
Increasing IMP-1 production increases fitness cost 168 
To further test the hypothesis that the amount of MBL protein production is a major 169 
part of the fitness cost imposed by carrying MBL genes and to exclude any NDM-1 170 
specific effects, we aimed to increase IMP-1 production. To do this we turned to our 171 
recently reported blaIMP-1 synonymous lysine codon variant, IMP-1-KV where 17 AAA 172 
lysine codons were converted to the alternative synonymous codon, AAG (23). LC-173 
MS/MS proteomics showed that the amount of IMP-1 produced from the variant 174 
blaIMP-1-KV was 2.2-fold (p=0.005) more than from wild-type blaIMP-1 in E. coli (Fig. 2). 175 
As hypothesised, this increase in IMP-1 protein production was associated with an 176 
increase in fitness cost, which was approximately 7% per day in E. coli and 177 
approximately 20% per day in K. pneumoniae (p<0.001 for both comparisons) (Table 178 
1). We attempted to repeat this experiment by cloning blaIMP-1 downstream of a 179 
strong integron promoter, which drives high-level gene expression, but very few E. 180 
coli transformants were recovered. In all cases, the transformants had mutations 181 
upstream of blaIMP-1 expected to reduce gene expression, e.g. those affecting the -35 182 
or -10 promoter sequences or the spacing in between. Accordingly, we conclude that 183 
the fitness cost of carrying this highly expressed form of blaIMP-1 is too great for 184 





Reduced NDM-1 production due to rearrangements in the blaNDM-1 promoter region 187 
explains lack of meropenem resistance in Enterobacter spp. isolates from a clinical 188 
case. 189 
A patient was admitted directly to the intensive care unit after developing a small 190 
bowel obstruction and an aspiration pneumonia. Bronchoalveolar lavage grew 191 
Citrobacter freundii, K. pneumoniae and Bacteroides vulgatus. The patient was 192 
initially treated with piperacillin-tazobactam and azithromycin and noted to have a 193 
strangulated inguinal hernia which was repaired. Two days after admission, the 194 
patient was escalated to meropenem due to continued fever. Vancomycin was 195 
added for a possible coagulase negative Staphylococcus spp. line infection. They 196 
continued to require ventilation and a tracheostomy was performed on day 7. By 20 197 
days after admission, symptoms had resolved and C-reactive protein had fallen to 10 198 
from 368 mg/L on admission, and meropenem was stopped.  199 
Five days later, fever restarted, and a sputum sample grew K. pneumoniae resistant 200 
to piperacillin-tazobactam and ciprofloxacin, but Extended-Spectrum β-Lactamase 201 
(ESBL) negative and susceptible to third-generation cephalosporins. Ceftazidime 202 
and vancomycin were started. After 6 days of ceftazidime, a routine multi-resistant 203 
coliform screen of the patient’s tracheostomy site noted a ceftazidime resistant 204 
Enterobacter spp. (Ent1). This was ESBL positive and had a multi-drug resistance 205 
phenotype (Table S7). Due to an apparently raised meropenem MIC, a Cepheid 206 
Xpert-Carba R PCR test was performed, suggesting the presence of blaNDM. Despite 207 
this, Ent1 was not meropenem resistant and so ceftazidime treatment was switched 208 
to meropenem. After 10 days of meropenem, the patient improved, and antibiotic 209 
therapy was discontinued. Routine screens continued to isolate Enterobacter spp. 210 




after the isolation of Ent1, another routine screen identified an ESBL negative K. 212 
pneumoniae, which was fully resistant to meropenem (KP3), as well as to third-213 
generation cephalosporins, piperacillin-tazobactam and ciprofloxacin (Table S7). 214 
The Cepheid Xpert-Carba also identified blaNDM in KP3. The patient, however, 215 
remained well and continued off antibiotics and was discharged to the surgical ward. 216 
Subsequent routine screens continued to identify this meropenem resistant K. 217 
pneumoniae and the blaNDM positive Enterobacter spp. that was not meropenem 218 
resistant and specialist infection control precautions were continued. 219 
Whole genome sequence (WGS) analysis of the Enterobacter spp. isolates Ent1 and 220 
Ent2 showed them to be Enterobacter hormaechei and confirmed that blaNDM-1 is 221 
present on the same IncFIB(K) plasmid in both. The plasmid was assembled into a 222 
single contig of 84,659 nt carrying genes conferring resistance to 223 
amikacin/ciprofloxacin (aacA4-cr), rifampicin (arr-3), co-trimoxazole (sul1) and 224 
streptomycin (aadA1), all part of the same complex class 1 integron alongside 225 
blaNDM-1. Otherwise, on the chromosome, other relevant resistance genes carried by 226 
Ent1 and Ent2 were to ampicillin (blaTEM-1), and the expected ESBL (blaCTX-M-15). The 227 
isolates also carried chromosomal mutations in gyrA (Ser83Ile) and parC (Ser80Ile) 228 
causing ciprofloxacin resistance. Collectively this acquired resistance genotype 229 
explains the antibiograms of Ent1 and Ent2, except for the fact that meropenem 230 
resistance should have been provided by the blaNDM-1 gene but was not. 231 
LC-MS/MS proteomics revealed that NDM-1 production was the same in Ent1 and 232 
Ent2. The amount normalised to ribosomal proteins was 0.41 +/- 0.03 (mean +/- SD), 233 
which was not significantly different (p=0.13) from the amount of IMP-1 produced 234 
from its native PcH1 promoter in blaIMP-1 transformants of E. coli and K. pneumoniae 235 




Ent2 was significantly different from (p<0.0005), and approximately 6-fold less than 237 
NDM-1 production in transformants of E. coli and K. pneumoniae where blaNDM-1 was 238 
expressed from the typical ISAba125 Pout promoter (3.24 +/- 0.69, Fig. 1). This low-239 
level production of NDM-1 in Ent1 and Ent2 likely explains why these isolates are not 240 
meropenem resistant (MIC<4 mg/L), as seen for blaIMP-1  transformants (Table S2). 241 
To explain the reason for low-level NDM-1 production in Ent1 and Ent2, we 242 
compared the sequence upstream of blaNDM-1 in these two isolates with those from E. 243 
coli IR10, the source of the recombinant plasmids used above, and from K. 244 
pneumoniae KP05-506, which is the original isolate from which blaNDM-1 was 245 
identified (8). We found a significant rearrangement immediately adjacent to the 246 
ISAba125 Pout promoter in Ent1 and Ent2 (Fig. 3). There has been an insertion of an 247 
element containing a truncated blaOXA-10 gene.  248 
The upstream variation seen in Ent1 is rare but not unique. It matched to 14 NCBI 249 
database entries reporting isolates collected in China, Taiwan, Japan, Pakistan, and 250 
the UK (Table S8). Notably, but not commented on by the authors, an E. coli 251 
transconjugant carrying plasmid pLK78, encoding blaNDM-1 with this blaOXA-10 252 
upstream insertion, was not meropenem resistant (24). Moreover, isolates from 253 
Pakistan where the blaOXA-10 insertion upstream of blaNDM-1 was identified in several 254 
related plasmids (25) were originally collected in 2010 and the authors noted that 255 
53% of NDM-1 producing isolates were meropenem susceptible (26). 256 
 257 
Low-level NDM-1 production confers meropenem resistance in a background with 258 




Isolate KP3, from the same clinical case, was meropenem resistant. LC-MS/MS 260 
proteomics analysis confirmed that KP3 produced NDM-1 at the same level as Ent1 261 
and Ent2. WGS showed that as well as carrying blaNDM-1, aacA4-cr, sul1, arr-3 and 262 
aadA1 on an IncFIB(K) plasmid identical to that found in Ent1 and Ent2, KP3 carried 263 
blaTEM-1 and blaOXA-9, found together on a second plasmid, plus the chromosomal 264 
blaSHV-1. KP3 also has Ser83Phe and Asp87Ala mutations in GyrA plus a Ser80Ile 265 
mutation in ParC explaining ciprofloxacin resistance.  266 
The β-lactamases produced by KP3 in addition to NDM-1 cannot explain the very 267 
much higher MIC of meropenem against KP3 versus Ent1 and Ent2. Analysis of KP3 268 
WGS data for known factors that contribute to carbapenem resistance revealed only 269 
one: that KP3 is a ramR mutant, having an 8 nt insertion into ramR after nucleotide 270 
126, causing a frameshift. We have shown that loss of RamR in K. pneumoniae 271 
leads to enhanced AcrAB-TolC efflux pump production, reduced OmpK35 porin 272 
production, and enhanced carbapenem MICs in the presence of weak 273 
carbapenemases (27). Hence this mutation in KP3 enhances the meropenem MIC 274 
against KP3, making it resistant despite low-level production of NDM-1 due to 275 
modification of the ISAba125 outward facing promoter region by insertion of a 276 
truncated blaOXA-10. 277 
 278 
Conclusions 279 
Overall, we have observed that modest expression of blaIMP-1 from a native 280 
intermediate strength integron common promoter (PcH1), which is regularly seen in 281 
blaIMP-1 clinical isolates, does not provide meropenem resistance in representative 282 




is expressed at higher levels from its native ISAba125 outward facing promoter and 284 
this gives higher meropenem MICs, confers resistance as defined by clinical 285 
breakpoints, but this comes with a significant fitness cost. A fitness cost associated 286 
with carrying blaNDM-1 was also found in a previous report (28). We conclude that the 287 
likely reason for this fitness cost is that NDM-1 is produced at high levels when 288 
blaNDM-1 is expressed from its native promoter. The obvious explanation is that 289 
producing a large amount of a non-native protein results in amino acid depletion, 290 
which drives the cell to switch on amino acid biosynthetic pathways, which was 291 
observed in our proteomic analysis. Whilst this maintains the supply of amino acids 292 
for protein synthesis, it diverts carbon that would otherwise be available to other 293 
processes required for cell growth. This effect may be exaggerated in the case of 294 
NDM-1, since it is targeted to the outer membrane, where it can be lost within 295 
microvesicles (29). There was no evidence of zinc starvation stress in our 296 
proteomics data, though presumably at lower zinc concentrations the fact that NDM-297 
1 is a zinc containing enzyme could exacerbate the fitness cost. Our fitness assays 298 
were performed using a medium containing 6.2 µM zinc and the broth used to 299 
perform MIC testing and proteomics contains ~4 µM zinc (30). The normal human 300 
serum concentration of zinc as ~12 µM (31) but clearly, long term selection pressure 301 
on Enterobacterales is perhaps more likely to occur outside the human body, where 302 
zinc concentrations may be very much lower even than in our assays. 303 
Our findings provide a real-world example of fitness/resistance trade-offs. It may be 304 
that the reason for blaNDM-1 being so common in carbapenem resistant 305 
Enterobacterales is repeated selective pressure via carbapenem use, driving its 306 
presence despite the cost. Alternatively, natural plasmids or certain strains carrying 307 




accumulated mutations that compensate for reduced fitness. This could come 309 
without the expense of reduced carbapenem MICs, e.g., if an NDM produced at 310 
lower levels was a variant more efficient at catalysing the hydrolysis of meropenem. 311 
But in the case reported here, we have identified the insertion of a truncated blaOXA-312 
10, damaging the blaNDM-1 promoter region and reducing NDM-1 production in 313 
Enterobacter spp. isolates from a clinical case, a genetic arrangement found in 314 
commensal carriage Enterobacterales isolates from as far back as 2010 (26).  315 
Low-level NDM-1 producers avoid the fitness cost associated with wild-type blaNDM-1 316 
carriage but, consequently, are not meropenem resistant. Though they remain 317 
cephalosporin resistant, and so are likely to be maintained in an environment where 318 
cephalosporins are used. This highlights a potential infection control issue where 319 
phenotypic meropenem resistance is necessary for a positive screening outcome. As 320 
seen here, the isolates Ent1 and Ent2 were still identified as being of interest due to 321 
extra vigilance in respect of a seriously ill patient. With less vigilance, it may have 322 
been that the only notice of the presence of an NDM-1 producing isolate in or around 323 
this patient would have been following mobilisation of the blaNDM-1 encoding plasmid 324 
into the ramR mutant K. pneumoniae with reduced envelope permeability, to create 325 
meropenem resistant isolate KP3. This ability of reduced envelope permeability to 326 
enhance meropenem MIC against a low-level MBL producer may also explain our 327 
finding that blaIMP-1 is more common in P. aeruginosa, a species renowned for having 328 
much lower envelope permeability than wild-type Enterobacterales (32). In the 329 
context of “under the radar” NDM-1 production defined here, which also relies on 330 
reduced envelope permeability, we show that sudden emergence of clinically-331 








Bacteria Used and Susceptibility Testing Assays 337 
Bacterial strains used in the study were E. coli MG1655 (33) and a collection of 338 
human clinical isolate from urine (a gift from Dr Mandy Wooton, Public Health 339 
Laboratory for Wales), a human clinical isolate of K. aerogenes, NDM-1 producing 340 
isolates of E. coli IR10 and K. pneumoniae KP05_506 (gifts from Prof T Walsh, 341 
University of Oxford), and K. pneumoniae strains SM, ECL8 and NCTC 5055 (34). 342 
Antibiotic susceptibility was determined using disc testing or broth microdilution MIC 343 
assays according to EUCAST guidelines. Cation-Adjusted Mueller-Hinton Broth 344 
(CAMHB) was purchased from Sigma. 345 
 346 
Molecular Biology 347 
Creation of pSUHIMP, being the cloned blaIMP-1 gene downstream of a native PcH1 348 
was via PCR using template DNA from P. aeruginosa clinical isolate 206-3105A (a 349 
gift from Dr Mark Toleman, Department of Medical Microbiology, Cardiff University). 350 
The sequence of plasmid pYUI-1, the blaIMP-1 encoding plasmid from this isolate has 351 
been deposited under GenBank accession number MH594579. PCR used a forward 352 
primer targeting the 5’ end of the PcH1 promoter (5’-353 
ACCCAGTGGACATAAGCCTGTTCGGTTCGTAAACT-3’) and a reverse primer 354 
targeting the 5’ end of a blaOXA-1 gene cassette, which is downstream of blaIMP-1 in 355 




cloned into the pCR2.1TOPO cloning vector (Invitrogen), removed with EcoRI and 357 
ligated into EcoRI linearized broad host range p15A-derived vector pSU18 (35). Site 358 
directed mutagenesis to create pSUHIMP-KV containing 14 AAA-AAG transitions 359 
was performed using the methods and primers previously reported (23). Creation of 360 
pSUNDM, being the cloned blaNDM-1 gene downstream of its native ISAba125 361 
promoter in plasmid pSU18 has been reported previously (36). Site directed 362 
mutagenesis using pSUNDM as the template was performed using the QuikChange 363 
Lightning Site-Directed Mutagenesis Kit (Agilent, UK) according to the 364 
manufacturer’s instructions. The aim was to convert the native ribosome binding site 365 
upstream of blaNDM-1 (AAAAGGAAAACTTGATGAGCAAGTTATCT) to be the same 366 
as that upstream of blaIMP-1 (AAAAGGAAAAGTATGAGCAAGTTATCT – differences 367 
underlined), using the mutagenic primer 5’-368 
GGGGTTTTTAATGCTGAATAAAAGGAAAAGTATGGAATTGCCCAAT-3’. The 369 
resultant plasmid was named pSUNDM-RBS. Switching the entire upstream 370 
sequence from the ATG of blaNDM-1 to be the same as blaIMP-1 was performed by 371 
gene synthesis recreating the entire pSUNDM insert sequence, but with the same 372 
upstream sequence carried in pSUHIMP. The resultant plasmid was named 373 
pSUNDM-N* 374 
 375 
Proteomic Analysis 376 
A volume of 1 ml of overnight liquid culture was transferred to a 50 ml of fresh 377 
CAMHB and incubated at 37°C until an OD600 of 0.5-0.6 was achieved. Samples 378 
were centrifuged at 4,000 rpm for 10 min at 4˚C and the supernatants discarded. 379 
Cells were re-suspended into lysis buffer (35 ml of 30mM Tris-HCl pH 8) and broken 380 




Sonics Vibracell VC-505TM (Sonics and Materials Inc., Newton, Connecticut, USA). 382 
This was followed by centrifugation at 8000 rpm (Sorval RC5B PLUS using an SS-34 383 
rotor) for 15 min at 4°C to pellet non-lysed cells. Soluble proteins were concentrated 384 
to a volume of 1 ml using centrifugal filter units (AMICON ULTRA-15, 3 KDa cutoff). 385 
Then, the concentration of the proteins in each sample was measured using Biorad 386 
Protein Assay Dye Reagent Concentrate according to the manufacturer’s 387 
instructions and normalised. LC-MS/MS was performed and analysed as described 388 
previously (37) using 5 µg of protein for each run. Analysis was performed in 389 
triplicate, each from a separate batch of cells. Protein abundance was normalised 390 
using the average abundance of ribosomal proteins, unless stated in the text. 391 
 392 
Measurement of meropenem hydrolysis 393 
Twenty microlitres of concentrated total cell protein (prepared and assayed for 394 
concentration as above) was transferred to 180 µl of 50 mM HEPES (pH 7.5) 395 
containing 50 µM ZnSO4 and 100 µM meropenem. Change of absorbance was 396 
monitored at 299 nm over 10 min. Specific enzyme activity (pmol meropenem 397 
hydrolysed per milligram of protein per second) in each extract was calculated using 398 
9600 M-1 as the extinction coefficient of meropenem and dividing enzyme activity 399 
with the total amount of protein in each assay. 400 
 401 
Pairwise Fitness Cost Experiments 402 
Pairwise competition experiments were performed by using M9 minimal medium to 403 
evaluate the fitness cost of carrying pSUHIMP, pSUHIMP-KV or pSUNDM, each 404 




both transformants in the pairwise competition were established separately in LB 406 
broth at 37˚C with shaking at 160 rpm. Then, 5 µl of each overnight liquid culture was 407 
inoculated into 10 ml M9 minimal medium separately in flasks and incubated as 408 
above for 24 h as before. After this incubation, 5 µl of each overnight M9 minimal 409 
medium was again inoculated separately into 10 ml M9 minimal medium as before 410 
and grown overnight. The next day, for each competing bacterium, 75 µl of the 411 
previous day’s culture was inoculated into fresh 15 ml M9 minimal medium to obtain 412 
a mixed culture (day one). After 24 h of incubation, 150 µl of the mixed culture was 413 
transferred into a fresh 15 ml M9 minimal medium to obtain the day-two culture. 414 
Then, this step was performed successively until the day-four mixed liquid culture 415 
was attained. For each pairwise competition experiment, the above process was 416 
carried out six times in parallel and on each day, the colony forming units per ml 417 
(cfu/ml) of the two bacteria was counted in triplicate using LB agar selective for the 418 
cloning vector (the total count of both competitors, as both are chloramphenicol 419 
resistant) and agar containing 20 mg/L ceftazidime (to count bacteria producing IMP-420 
1 or NDM-1). The pSU18 containing transformant count was calculated by 421 
subtracting the pSUHIMP or pSUNDM containing transformant count from the total 422 
count of bacteria in the competition.   423 
The fitness cost of the resistant strain relative to the sensitive strain was estimated 424 
by calculating the Malthhusian parameter of the strain (M) as described (38):   425 
M= 1n (N1/N0)   426 
Where N0 indicates the density of the strain at the start of the day (cfu/ml) and N1 427 
represents the density of the strain at the end of the day (cfu/ml).   428 




W= M1/M2   430 
Where M1 represents growth of the sensitive strain and M2 refers to growth of the 431 
resistant strain. If R is positive, then M1>M2 which implies that the sensitive strain 432 
grows faster than the resistant strain and as a result has a fitness advantage and 433 
vice versa.   434 
For each day of competition, 36 values are achieved as for each pair-wise 435 
competition there are 6 R values and there are 6 competitions each day (6 mixed 436 
cultures a day). 437 
Differences in the two sets of data for each pairwise comparison were assessed 438 
using mean and standard deviation of R, and an unpaired t-test (with Welch’s 439 
correction) was used to assess the statistical significance of the differences 440 
observed. 441 
 442 
Analysis to identify clustering of differentially regulated proteins 443 
The KEGG Mapper tool: http://www.genome.jp/kegg/tool/map_pathway2.html was 444 
used. We searched against E. coli MG1655 (organism: eco) and entered a list of the 445 
Uniprot accession numbers for the differentially regulated proteins. As a control, an 446 
equal number of E. coli MG1655 Uniprot accession numbers was randomly selected 447 
and entered in the KEGG Mapper as above. To determine the total number of 448 
proteins in the E. coli MG1655 proteome that fall into each KEGG, the entire Uniprot 449 
MG1655 accession number list was used to feed the KEGG Mapper tool. These 450 
values were used to perform a 2 analysis considering the significance of clustering 451 
of differentially regulated proteins by reference to random proteins into a KEGG 452 




performed 10 times, each with a different list of random proteins and the result 454 
reported was the lowest 2 value obtained across all 10 comparisons. 455 
 456 
WGS and data analysis 457 
Genomes were sequenced by MicrobesNG (Birmingham, UK) on a HiSeq 2500 458 
instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic 459 
(39) and assembled into contigs using SPAdes (40) 3.13.0 460 
(http://cab.spbu.ru/software/spades/) and contigs were annotated using Prokka (41). 461 
The presence of plasmids and resistance genes was determined using 462 
PlasmidFinder (42) and ResFinder 2.1 (43). 463 
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Table 1. Fitness effect of carrying blaIMP-1 or blaNDM-1 in E. coli and K. 
pneumoniae 
 




E. coli MG1655 
pSU18 vs pSUH IMP +4.5 0.5 
pSU18 vs pSU NDM -8.0 0.4 




pSU18 vs pSUH IMP +5.9 0.6 
pSU18 vs pSU NDM -29.3 0.7 








Figure 1. MBL Production in Enterobacterales carrying blaIMP-1 or blaNDM-1 with 
variant upstream sequences. 
MBL production was measured in K. pneumoniae, E. coli or K. aerogenes (Ent. 
aerogenes) recombinants carrying the pSU18 cloning vector, into which had been 
ligated blaIMP-1 with its upstream Pc(H1) promoter (dark blue bars), blaNDM-1 with its 
wild-type ISAba125 promoter (bed bars), blaNDM-1 with site directed mutation to 
convert its ribosome binding site to be identical to that upstream of blaIMP-1 (N RBS, 
light blue bars), and blaNDM-1 synthesised to have the same upstream sequence as 
blaIMP-1 (N*, purple bars). In (A) meropenem hydrolysing activity (nmol.min-1.mg total 
protein-1) was measured in whole cell extracts. In (B) IMP-1 or NDM-1 protein 
abundance derived from LC-MS/MS analysis of whole cell extracts is reported 
normalised to the average abundance of 30S and 50S ribosomal proteins in each 
extract. Data are means +/- Standard Error of the Mean, n=3. 
 
Figure 2. Increased production of IMP-1 following introduction of 17 AAA-AAG 
lysine codon variants into blaIMP-1. 
E. coli MG1655 recombinants carry pSU18 with blaIMP-1 or a variant (22) in which 17 
AAA lysine codons had been mutated to AAG (IMP-1-KV) were analysed. IMP-1 
protein abundance derived from LC-MS/MS analysis of whole cell extracts is 
reported normalised to the average abundance of 30S and 50S ribosomal proteins in 




Figure 3. Altered Upstream Sequence in Ent1/2 and KP3 versus blaNDM-1 Source 
Sequences. 
The Clustal Omega alignment used WGS data from two isolates carrying wild-type 
blaNDM-1: E. coli IR10 and K. pneumoniae KP05-506 plus the sequence shared by 
clinical isolates Ent1, Ent 2 and KP3. Identities across all three sequences are 





















Figure 3.  
 
KP05_506      -------acaccattagagaaatttgctcagcttgttgattatcatatggcttttgaaac 53 
IR10          -------acaccattagagaaatttgctcagcttgttgattatcatatggcttttgaaac 53 
Ent1          ccagctaatgccgta----ctcgaaagacagcttgttgattatcatatggcttttgaaac 56 
                     *  ** *              ******************************** 
 
KP05_506      tgtcgcacctcatgtttgaattcgccccatatttttgctacagtgaaccaaattaagatc 113 
IR10          tgtcgcacctcatgtttgaattcgccccatatttttgctacagtgaaccaaattaagatc 113 
Ent1          tgtcgcacctcatgtttgaattcgccccatatttttgctacagtgaaccaaattaagatc 116 
              ************************************************************ 
 
